EQU-001 is under clinical development by Equilibre Biopharmaceuticals and currently in Phase II for Partial Seizure. According to GlobalData, Phase II drugs for Partial Seizure have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EQU-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EQU-001 overview

EQU-001 is under development for the treatment of epilepsy and uncontrolled focal onset seizures (partial seizures). It is administered through oral route in the form of capsule.

Equilibre Biopharmaceuticals overview

Equilibre Biopharmaceuticals (Equilibre) is a biopharmaceutical company that discovers, develops and delivers treatments for neurodegenerative diseases. It is investigating drugs to treat nonepileptic and epileptic seizure disorders, traumatic brain injury, and spasticity associated with spinal cord injury. The company is also evaluating treatments for behavioural epileptic seizures (BES), Lennox-Gastaut, Dravent, CDKL5 deficiency syndrome and other epileptic encephalopathies. Equilibre is headquartered in New York, the US.

For a complete picture of EQU-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.